Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | pyruvate kinase | 0.0033 | 0.84 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 1 | 1 |
Schistosoma mansoni | pyruvate kinase | 0.0033 | 0.84 | 0.84 |
Trypanosoma brucei | pyruvate kinase 1 | 0.0033 | 0.84 | 0.5 |
Echinococcus multilocularis | pyruvate kinase | 0.0033 | 0.84 | 0.84 |
Onchocerca volvulus | Pyruvate kinase homolog | 0.0033 | 0.84 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 1 | 1 |
Toxoplasma gondii | pyruvate kinase PyK1 | 0.0033 | 0.84 | 1 |
Chlamydia trachomatis | pyruvate kinase | 0.0033 | 0.84 | 0.5 |
Trypanosoma cruzi | pyruvate kinase 2, putative | 0.0033 | 0.84 | 0.5 |
Trichomonas vaginalis | pyruvate kinase, putative | 0.0033 | 0.84 | 0.5 |
Leishmania major | pyruvate kinase | 0.0033 | 0.84 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0036 | 1 | 1 |
Loa Loa (eye worm) | pyruvate kinase | 0.0033 | 0.84 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 1 | 1 |
Echinococcus granulosus | pyruvate kinase | 0.0033 | 0.84 | 0.84 |
Loa Loa (eye worm) | pyruvate kinase | 0.0033 | 0.84 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0036 | 1 | 1 |
Plasmodium falciparum | pyruvate kinase | 0.0033 | 0.84 | 1 |
Giardia lamblia | Pyruvate kinase | 0.0033 | 0.84 | 1 |
Echinococcus multilocularis | pyruvate kinase | 0.0033 | 0.84 | 0.84 |
Trypanosoma brucei | pyruvate kinase 1, putative | 0.0033 | 0.84 | 0.5 |
Mycobacterium tuberculosis | Probable pyruvate kinase PykA | 0.0033 | 0.84 | 0.5 |
Onchocerca volvulus | Pyruvate kinase homolog | 0.0033 | 0.84 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0036 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.84 | 1 |
Echinococcus multilocularis | pyruvate kinase | 0.0026 | 0.4764 | 0.4764 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0036 | 1 | 1 |
Trypanosoma cruzi | pyruvate kinase 2, putative | 0.0033 | 0.84 | 0.5 |
Leishmania major | pyruvate kinase | 0.0033 | 0.84 | 0.5 |
Onchocerca volvulus | Pyruvate kinase homolog | 0.0033 | 0.84 | 0.5 |
Trichomonas vaginalis | pyruvate kinase, putative | 0.0033 | 0.84 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 1 | 1 |
Mycobacterium leprae | Probable pyruvate kinase PykA | 0.0033 | 0.84 | 0.5 |
Echinococcus granulosus | pyruvate kinase | 0.0033 | 0.84 | 0.84 |
Loa Loa (eye worm) | pyruvate kinase | 0.0033 | 0.84 | 1 |
Schistosoma mansoni | pyruvate kinase | 0.0033 | 0.84 | 0.84 |
Plasmodium vivax | pyruvate kinase, putative | 0.0033 | 0.84 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 1.91 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 2 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 4.08 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 5 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition (functional) | = 6.23 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 20 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 90 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition frequency index (IFI) (functional) | = 0.76 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 2 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 5 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 20 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 90 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
XC50 (functional) | = 5.99 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
XC50 (functional) | = 1.0136 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.